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Background:  Drug-induced hyperglycemia and new-onset diabetes mellitus (DM) after heart transplantation (HT) are recognized 
complications of anti-rejection pharmacotherapy comprising glucocorticoids and calcineurin inhibitors such as tacrolimus. Diabetic 
ketoacidosis (DKA) however, is a serious emergency seldom seen as an adverse drug effect following HT.
case:  A 32-year-old female with orthotopic HT 2½ months prior presented with acute polydipsia, polyuria, nausea and abdominal pain. Her 
comprehensive pre-transplant work-up was negative for systemic diseases, including DM. Her pre-HT glycated hemoglobin (HbA1c) was 
5.2% without any documented hyperglycemia. Her antirejection regimen comprised tacrolimus, mycophenolate and a tapering regimen of 
glucocorticoids.
decision Making:  Her clinical examination was notable only for tachycardia. Her blood and urine tests revealed hyperglycemia (676mg/
dl), ketonemia (beta-hydroxybutyrate level: 8.2 mmol/L), high anion gap metabolic acidosis (anion gap: 21, bicarbonate:16 mmol/L), 
heavy ketonuria and glucosuria. Her clinical presentation and laboratory data confirmed DKA and she was started on a standardized 
protocol of intravenous insulin and fluid replacement. An infection work-up was negative. Her chest, abdominal and cardiac imaging were 
unremarkable. Glutamic acid decarboxylase (GAD) antibodies were negative. No identifiable precipitating factors were noted except for 
her immunosuppressive medications. Glucocorticoids are known to cause insulin insensitivity and increased hepatic glucose production 
while tacrolimus impedes insulin synthesis by unclear mechanisms leading to insulin deficiency which in turn is the hallmark of DKA 
pathogenesis. Her clinical status improved with resolution of symptoms and normalization of her laboratory values. She was initiated on 
subcutaneous insulin and her anti-rejection medications were continued unaltered.
conclusion:  This case highlights DKA as a potentially life-threatening adverse effect of anti-rejection drugs, notably glucocorticoids and 
tacrolimus. Though rare, post HT patients need careful and routine monitoring for development of DM and DKA.
